ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO167

Trajectory of Glomerular Filtration Rate Decline and Fluctuation in Albuminuria Leading to ESKD: An Observational Cohort Study of Biopsy-Confirmed Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Author

  • Yamanouchi, Masayuki, Toranomon Byoin, Minato-ku, Tokyo, Japan
Background

Data on trajectory of kidney function decline and fluctuation in albuminuria leading to end-stage kidney disease (ESKD) is sparse in patients with type 2 diabetes.

Methods

Using data from an observational study of biopsy-confirmed diabetic kidney disease (DKD), panel data analyses were performed to quantify patterns of trajectory of estimated glomerular filtration rate (eGFR) decline to ESKD associated with repeated measures of urine albumin-to-creatinine ratio (ACR).

Results

During a median follow-up of 3.25 years, 156 out of 312 developed ESKD. Among them, 84.0% showed a curvilinear pattern of eGFR trajectory, 62.2% moved into a different albuminuria status from that at baseline, and 84.6% of patients developed nephrotic-range albuminuria, many of whom remained nephrotic. Mixed-effects models for repeated measures showed that speed of eGFR decline for normo- [ACR <30 mg/g], micro- [ACR 30 to <300 mg/g], macro- (non-nephrotic range albuminuria) [ACR 300 to <3000 mg/g] and nephrotic-range albuminuria [ACR ≥3000 mg/g] were -2.50 (95% CI, -8.62 to 3.62; P =0.423), -4.76 (95% CI, -8.94 to -0.57; P =0.026), -6.39 (95% CI, -8.31 to -4.48; P <0.001) and -9.51 (95% CI, -11.75 to -7.28; P <0.001) mL/min/1.73 m2/year, respectively.

Conclusion

Majority of patients with biopsy-confirmed DKD who developed ESKD showed a curvilinear eGFR trajectory with fluctuation in ACR. Although there were high inter- and intra-individual variability in changes in eGFR and ACR, ACR were inversely associated with eGFR decline, which suggests that close monitoring of ACR fluctuation over time instead of a single assessment of ACR may be necessary to detect eGFR decline to ESKD.